Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination

Cancer Research

Volumn 69, Issue 5, 2009, Pages 2026-2033

  Schreiber, Taylor H ^a   Deyev, Vadim V ^a   Rosenblatt, Joseph D ^a   Podack, Eckhard R ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 96; GLYCOPROTEIN GP 96 IMMUNOGLOBULIN G1 FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CANCER VACCINE; CXCL10 PROTEIN, MOUSE; ENDOPLASMIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; IMMUNOLOGY; LYMPHOMA; PHYSIOLOGY; TH1 CELL; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIGENS, CD11B; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINE CXCL10; CYTOTOXICITY, IMMUNOLOGIC; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-17; LYMPHOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSFORMING GROWTH FACTOR BETA; VACCINATION;

EID: 62449170994     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3706     Document Type: Article

References (41)

1. Smyth M], Dunn GP, Schreiber RD. Cancer immuno-surveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006:90:1.-50.
2. Mapara MY, Sykes M. Tolerance and cancer: mecha-nisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004:22:1136-1151
3. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immu-nosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007:25:267-296
4. Willimsky G, Czeh M, Loddenkemper C, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsive-ness. J Exp Med 2008:205:1.687-700.
5. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of Immunosuppressive networks during ma-lignant progression. Cancer Res 2006:66:5527-5536
6. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Ann Rev Immunol 2007:25:243-265
7. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008:68:2561-2563
8. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008:8: 467-477
9. Yamazakl K, Nguyen T, Podack ER. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejecUoa J Immunol 1999:163:5178-5182
10. Olzuml S, Deyev V, Yamazaki K, et al. Surmounting tumor-induced immune suppression by frequent vaccination or immunization, in the absence of B cells. J Immunother 2008:31:394-401.
11. Ikawa M, Yamada S, Nakanishi T, Okabe M. 'Green, mice' and their potential usage in. biological research. FEBS Lett 1998:430:83-87
12. Hofman F. Immunohlstochemistry. Current protocols in immunology. In: Coligan. JE, et al., editor. Chapter 21: Unit 21 4. 2002.
13. Olzuml S, Strbo N, Pahwa S, Deyev V, Podack ER. Molecular and cellular requirements for enhanced, antigen cross-presentation to CDS cytotoxic T lympho-cytes. J Immunol 2007:179:2310-2317
14. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008:68:5501-5504
15. Shojaei F, Zhong C1WiXKiI, Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008;18:372-378
16. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-983
17. Blerle B, Moses HL. Tumour microenvironment: TGFß: the molecular Jekyll and Hyde of cancer. Nature Rev 2006;6:506-520
18. Nam. JS, Terabe M, Kang MJ, et al. Transforming growth factor ß subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915-3923
19. Nam JS, Terabe M, Mamura M, et al. An. anti-transforming growth factor ß antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008:68:3835-3843
20. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-1./PD-1 axis and transforming growth factor ß. Cancer Res 2008:68:5432-5438
21. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007:318:1108-1113.
22. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008:321:1801-1806.
23. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human, glioblastoma multiforme. Science 2008:321:1807-1812.
24. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007:450:903-907
25. Démine R, Waiden P. Testing the role of gp96 as peptide chaperone in antigen processing. J Biol Chem 2005;280:17573-17578
26. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann Rev Immunol 2002;20:395-425.
27. Testorl A, Richards J, Whitman E, et al. Phase III comparison of vltespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008:26:955-962
28. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372:145-154
29. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 2008;222:222-241
30. Ishikawa S, Sato T, Abe M, et al. Aberrant high expression, of B lymphocyte chemokine (BLC/CXCL1.3) by Cllb+CDIIc+ dendritic cells in. murine lupus and preferential Chemotaxis of Bl cells towards BLC. J Exp Med 2001;193:1393-1402
31. Kottke T, Sanchez-Perez L, Diaz RM, et al. Induction of hsp70-mediated ThIV autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 2007:67:11970-11979
32. Muranski P, Boni A Antony PA, et al. Tumor-specific Thl7-polarized cells eradicate large established mela-noma. Blood 2008:112:362-373
33. Bronte V. Thl.7 and cancer: friends or foes? Blood 2008:112:214.
34. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004:22: 329-360
35. Shankaran. V Ikeda H, Bruce AT, et al. IFNY and lymphocytes prevent primary tumour development and shape tumour Immunogenicity. Nature 2001:410: 1107-1111
36. Smyth MJ, Thia KY, Cretney E, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999:162:6658-6662
37. Strbo N, Oizumi S, Sotosek-Tokmadzic V Podack. ER. Perforin is required for innate and adaptive immunity induced by heat shock protein. gp96. Immunity 2003:18: 381-390.
38. Massague J. TGFß in cancer. Cell 2008:134:215-230
39. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207:81-88
40. Quezada SA, Peggs KS, Simpson. TR, Shen Y, Liftman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melano-ma. J Exp Med 2008;205:2125-2138
41. Bargou R, Leo E, Zugmaier G, et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, 2008, 32, 974-97